Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $223.15 and last traded at $223.15, with a volume of 26 shares traded. The stock had previously closed at $250.08.
Bio-Rad Laboratories Stock Down 10.8%
The business's fifty day moving average price is $240.44 and its 200 day moving average price is $287.07. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $6.25 billion, a PE ratio of -3.43 and a beta of 0.82.
Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.54 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The business had revenue of $585.40 million for the quarter.
About Bio-Rad Laboratories
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
